Accutar Biotechnology Announces First Patient Dosed with AC0176 in Phase 1 Study in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
– Chimeric Degrader With a Differentiated Mechanism of Action vs. Androgen Receptor Inhibitors – –…